The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model

Biomed Res Int. 2013;2013:832404. doi: 10.1155/2013/832404. Epub 2013 Sep 23.


Background: Specific immunotherapy using recombinant allergens is clinically effective; still wild-type allergens can provoke treatment-induced side effects and often show poor immunogenicity in vivo. Thus, we tested the low IgE-binding, highly immunogenic fold variant BM4 in a Bet v 1 mouse model.

Methods: Recombinant BM4 was used as active vaccine ingredient to treat mice sensitized to Bet v 1. As controls, mice were treated with either Bet v 1 or sham, and the humoral as well as cellular immune response was monitored. Moreover, lung function and lung inflammation were analysed.

Results: BM4 was more effective than wild-type Bet v 1 in inducing Bet v 1-specific blocking antibodies as well as IFN-γ and IL-10 producing T cells. Further, birch pollen induced lung inflammation could be ameliorated significantly by BM4 treatment as demonstrated by a reduction of airway hyperresponsiveness and drastically decreased eosinophil counts in bronchoalveolar lavage fluids.

Conclusion: The study outlines the high potential of BM4 as vaccine candidate for the treatment of Bet v 1-mediated birch pollen allergies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Plant / chemistry
  • Antigens, Plant / genetics
  • Antigens, Plant / immunology
  • Antigens, Plant / pharmacology*
  • Disease Models, Animal
  • Female
  • Hypersensitivity / genetics
  • Hypersensitivity / immunology
  • Hypersensitivity / prevention & control*
  • Interferon-gamma / immunology
  • Interleukin-10 / immunology
  • Mice
  • Mice, Inbred BALB C
  • Protein Folding*
  • T-Lymphocytes / immunology
  • Vaccines / chemistry
  • Vaccines / genetics
  • Vaccines / immunology
  • Vaccines / pharmacology*


  • Antigens, Plant
  • IL10 protein, mouse
  • Vaccines
  • Bet v 1 allergen, Betula
  • Interleukin-10
  • Interferon-gamma